Solid Biosciences (SLDB) Cash from Investing Activities (2017 - 2026)

Solid Biosciences (SLDB) has 10 years of Cash from Investing Activities data on file, last reported at $44.8 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Investing Activities rose 262.98% year-over-year to $44.8 million; the trailing twelve-month figure through Mar 2026 stood at $13.8 million (up 372.13% YoY), and the FY2025 full-year result was -$58.5 million, down 263.38% from the prior year.
• Cash from Investing Activities eased to $44.8 million in Q1 2026, from $47.0 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $66.1 million in Q4 2022 to a low of -$59.6 million in Q2 2022.
• A 5-year average of $2.3 million and a median of -$5.2 million in 2024 frame the typical range for Cash from Investing Activities.
• Across the five-year window, Cash from Investing Activities soared 107937.14% in 2022 and slumped 532.38% in 2025, its largest moves.
• Tracing SLDB's Cash from Investing Activities over 5 years: stood at $66.1 million in 2022, then tumbled by 31.47% to $45.3 million in 2023, then declined by 14.86% to $38.6 million in 2024, then increased by 21.9% to $47.0 million in 2025, then retreated by 4.8% to $44.8 million in 2026.
• Business Quant data shows SLDB's Cash from Investing Activities at $44.8 million in Q1 2026, $47.0 million in Q4 2025, and -$45.3 million in Q3 2025.